Figure 1
From: A glucagon analogue decreases body weight in mice via signalling in the liver
Pharmacological profile of GCG104 in vitro and in vivo. (a) Primary structure of native GLP-1, glucagon (GCG), oxyntomodulin (OXM) and GCG104. Sequences are given in standard single amino acid code with Aib denoting alpha-amino isobutyric acid. (b) % max cAMP accumulation following GCG104, GLP-1 or glucagon treatment to HEK293 cells transiently expressing mGCGR or mGLP-1R (n = 4 for all tests). (c) Glucose response following vehicle or 10 nmol/kg GCG104 injection in 2 h fasted wild-type mice (n = 4 per group; 2-way ANOVA with Sidak post hoc test). (d) Corresponding glucose area under the curve for graph c (unpaired t test). (e) Pharmacokinetic profile of GCG104 in rats following 0.5 mg subcutaneous injection (n = 5 per group). All data presented as mean ± SEM. p values indicated by **p < 0.01, ****p < 0.0001.
